|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | New approaches in the treatment of hepatitis C显示文摘About 130-170 million people, is estimated to be infected with the hepatitis C virus(HCV). Chronic HCV infection is one of the leading causes of liverrelated death and in many countries it is the primaryreason for having a liver transplant. The main aim of antiviral treatment is to eradicate the virus. Until a few years ago the only treatment strategy was based on the combination of pegylated interferon and ribavirin(PEG/RBV). However, in genotypes 1 and 4 the rates of viral response did not surpass 50%, reaching up to 80% in the rest. In 2011 approval was given for the first direct acting antiviral agents(DAA), boceprevir and telaprevir, for treatment of genotype 1, in combination with traditional dual therapy. This strategy managed to increase the rates of sustained viral response(SVR) in both naive patients and in retreated patients, but with greater toxicity, interactions and cost, as well as being less safe in patients with advanced disease, in whom this treatment can trigger decompensation or even death. The recent, accelerated incorporation since 2013 of new more effective DAA, with pan-genomic properties and excellent tolerance, besides increasing the rates of SVR(even up to 100%), has also created a new scenario: shorter therapies, less toxicity and regimens free of PEG/RBV. This has enabled their almost generalised applicability in all patients. However, it should be noted that most of the scientific evidence available is based on expert opinion, case-control series, cohort studies and phase 2 and 3 trials, some with a reduced number of patients and select groups. Few data are currently available about the use of these drugs in daily clinical practice, particularly in relation to the appearance of side effects and interactions with other drugs, or their use in special populations or persons with the less common genotypes. This situation suggests the need for the generalised implementation of registries of patients receiving antiviral therapy. The main inconvenience of these new drugs is their high cost. This necessitates selection and prioritization of candidate patients to receive them, via strategies established by the various national organs, in accordance with the recommendations of scientific societies. | rocío gonzález-grande miguel jiménez-pérez carolina gonzález arjona josémostazo torres | 2016 | World Journal of Gastroenterology2016，22，4： | 9 |
| 2 | Management of hepatitis B virus infection after liver transplantation显示文摘Chronic hepatitis B virus(HBV) infection is responsible for up to 30% of cases of liver cirrhosis and up to 53% of cases of hepatocellular carcinoma. Liver transplantation(LT) is the best therapeutic option for patients with end-stage liver failure caused by HBV. The success of transplantation, though, depends on receiving prophylactic treatment against post-transplant viral reactivation. In the absence of prophylaxis, liver transplantation due to chronic hepatitis B(CHB) is associated with high rates of viral recurrence and poor survival. The introduction of treatment with hepatitis B immunoglobulins(HBIG) during the 1990 s and later the incorporation of oral antiviral drugs have improved the prognosis of these patients. Thus, LT for CHB is now a universally accepted option, with an estimated 5 years survival of around 85% vs the 45% survival seen prior to the introduction of HBIG. The combination of lamivudine plus HBIG has for many years been the most widely used prophylactic regimen. However, with the appearance of new more potent oral antiviral agents associated with less resistance(e.g., entecavir and tenofovir) for the treatment of CHB, new prophylactic strategies are being designed, either in combination with HBIG or alone as a monotherapy. These advances have allowed for more personalized prophylaxis based on the individual risk profile of a given patient. In addition, the small pool of donors has required the use of anti-HBc-positive donors(with the resulting possibility of transmitting HBV from these organs), which has been made possible by suitable prophylactic regimens. | Miguel Jiménez-Pérez Rocío González-Grande José Mostazo Torres Carolina González Arjona Francisco Javier Rando-Mu?oz | 2015 | World Journal of Gastroenterology2015，21，42： | 3 |
| 3 | Conservative management of perforated duodenal diverticulum: A case report and review of the literature显示文摘Duodenal diverticula are a relatively common condition. They are asymptomatic, unless they become complicated, with perforation being the rarest but most severe complication. Surgical treatment is the most frequently performed approach. We report the case of a patient with a perforated duodenal diverticulum, which was diagnosed early and treated conservatively with antibiotics and percutaneous drainage of secondary retroperitoneal abscesses. We suggest this method could be an acceptable option for the management of similar cases, provided that the patient is in good general condition and without septic signs. | David Martínez-Cecilia Alvaro Arjona Sánchez Manuel Gómez álvarez Eva Torres Tordera Antonio Luque Molina Victor Valentí Azcárate Javier Briceo Delgado Francisco Javier Padillo Pedro López-Cillero Sebastián Rufián Pea | 2008 | World Journal of Gastroenterology2008，14，12： | 2 |
| 4 | Preoperative calculation of angles of vision and working area in laparoscopic surgery to treat a giant hiatal hernia显示文摘BACKGROUND Giant hiatal hernias still pose a major challenge to digestive surgeons,and their repair is sometimes a highly complex task.This is usually performed by laparoscopy,while the role of the thoracoscopic approach has yet to be clearly defined.AIM To preoperatively detect patients with a giant hiatal hernia in whom it would not be safe to perform laparoscopic surgery and who,therefore,would be candidates for a thoracoscopic approach.METHODS In the present study,using imaging test we preoperatively simulate the field of vision of the camera and the working area(instrumental access)that can be obtained in each patient when the laparoscopic approach is used.RESULTS From data obtained,we can calculate the access angles that will be obtained in a preoperative computerised axial tomography coronal section,according to the location of the trocar.We also provide the formula for performing the angle calculations If the trocars are placed in loss common situations,thus enabling us to determine the visibility and manoeuvrability for any position of the trocars.CONCLUSION The working area determines the cases in which we can operate safely and those in which certain areas of the hernia cannot be accessed,which is when the thoracoscopic approach would be safer. | Francisco Javier Perez Lara Rogelio Zubizarreta Jimenez Francisco Javier Moya Donoso Jose Manuel Hernández Gonzalez Tatiana Prieto-Puga Arjona Arturo del Rey Moreno Maria Pitarch Martinez | 2021 | World Journal of Gastrointestinal Surgery2021，13，12： | 2 |
| 5 | Beta-endorphin neuro-nal cell transplant reduces corticotropin releasing hormone hyperre-sponse to lipopolysaccharide and eliminates natural killer cell func-tional deficiencies in fetal alcohol exposed rats显示文摘 | Boyadjieva NI Ortigüela M Arjona A | 2009 | Alcohol ClinExp Res2009，33，5： | 1 |
| 6 | Diffusional Effects in TGA Gasification Experiments for Kinetic Determination显示文摘 | Ollero P Serrera A Arjona R | 2002 | Fuel2002，81，： | 1 |
| 7 | Proximal migration of a Double J catheter:case report and review of the literature显示文摘 | Garrido Abad P Fernandez Arjona M Fernández González I | 2008 | Arch Esp Urol2008，61，3： | 1 |
| 8 | The CO2Gasication Kinetics of Olive Residue 显示文摘 | Ollero P Serrera A Arjona R | 2003 | Biomass & Bioenergy2003，24，： | 1 |
| 9 | Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renalinsufficiency显示文摘 | Chan JC Scott R Arjona Ferreira JC | 2008 | Diabetes Obes Metab2008，10，7： | 1 |
| 10 | Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes andmoderate-to-severe chronic renal insufficiency显示文摘 | Arjona Ferreira JC Marre M Barzilai N | 2013 | Diabetes Care2013，36，5： | 1 |
| 11 | Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial显示文摘 | Arjona Ferreira JC Corry D Mogensen CE | 2013 | Am J Kidney Dis2013，61，4： | 1 |
| 12 | Diffusional effects in TGA gasification experiments for kinetic determination显示文摘 | Ollero P Serrera A Arjona R | 2002 | Fuel2002，81，15： | 1 |
| 13 | Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency显示文摘 | Arjona Ferreira JC Matte M Barzilai N | 2013 | Diabetes Care2013，36，5： | 1 |
| 14 | Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo‐controlled 54‐week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究)*显示文摘 | Adrian S. DOBS Barry J. GOLDSTEIN Pablo ASCHNER Edward S. HORTON Guillermo E. UMPIERREZ Lorraine DURAN Julie S. HILL Yu CHEN Gregory T. GOLM Ronald B. LANGDON Debora E. WILLIAMS‐HERMAN Keith D. KAUFMAN John M. AMATRUDA Juan Camilo ARJONA FERREIRA | 2013 | Journal of Diabetes2013，，1： | 1 |
| 15 | Beta-endorphin neu- ronal cell transplant reduces corticotropin releasing hormone hy- perresponse to lipopolysaccharide and eliminates natural killer cell functional deficiencies in fetal alcohol exposed rats显示文摘 | Boyadjieva NI Ortigtlela M Arjona A | 2009 | Alcohol Clin Exp Res2009，33，5： | 1 |
| 16 | Optical quality of foldable monofocal intraocular lenses before and after injection: comparative evaluation using a double-pass system 显示文摘 | Vilaseca M Arjona M Pujol J | 2009 | J Cataract Refract Surg2009，35，8： | 1 |
| 17 | The CO2 Gasification Kinetics of Olive Residue显示文摘 | Ollero P Serrera A Arjona R | 2003 | Biomass and Bioenergy2003，24，2： | 1 |
| 18 | Reproducible and con- trollable light induction of in vitro fruiting of the white-rot basidio- mycete Pleurotus ostreatus显示文摘 | Arjona D Aragon C Aguilera J A | 2009 | Mycol Res2009，，113： | 1 |
| 19 | Early prophylactic treatment in pregnant women during the 2009-2010 H1N1 pandemic: obstetric and neonatal outcomes 显示文摘 | Nieto - Pascual L Arjona - Berral JE Marln - Martin EM | 2013 | J Obstet Gynaecol2013，33，2： | 1 |
| 20 | Triple combination therapy with sitaglipin, metformin and rosiglitazone improves glycemic control in patients with type 2 diabetes显示文摘 | Arjona Ferreira JC Dobs A Goldstein B J | 2008 | Diabetologia2008，51，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员